Warren, United States
Aquestive Therapeutics is a pharmaceutical company that aims to address the limitations of current standard treatments and enhance patients' quality of life. Established in 2004, the company focuses on developing orally administered products to deliver complex molecules, offering more convenient and non-invasive alternatives to existing therapies.
The company boasts five commercialized products in the U.S. market, with an additional four licensed products and one proprietary product, Sympazan® (clobazam) oral film, specifically designed for treating seizures associated with Lennox-Gastaut Syndrome. Moreover, Aquestive collaborates with other pharmaceutical firms to introduce new molecules via its proprietary technology, PharmFilm®.
Aquestive's last investment, totaling $75.00M, was in the form of Post-IPO Equity in March 19, 2024. Although the specific investors for this round are not disclosed, this investment showcases confidence in the company and its innovative approach to developing treatments for central nervous system diseases and severe allergic reactions like anaphylaxis.
This trajectory positions Aquestive Therapeutics as a compelling player in the pharmaceutical industry, with a focus on addressing unmet medical needs and striving for impactful advancements in patient care.
